FAQ

TRU 016

Known as: TRU-016 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
02420092017

Related topics

Related topics

3 relations

Broader (2)

Immunoglobulin GRecombinant Fusion Proteins

Narrower (1)

otlertuzumab

Related mentions per year

Related mentions per year

1964-2018
1960198020002020
TRU 016
Immunoglobulin G
Recombinant Fusion Proteins
otlertuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that triggers direct caspase-independent apoptosis of… (More)
  • table I
  • table II
  • table IV
  • table V
  • table III
Is this relevant?
2015
2015
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(â„¢) therapeutic protein, for relapsed or refractory NHL patients.
CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37… (More)
  • table I
  • figure 1
  • figure 2
  • table II
  • table III
Is this relevant?
2014
2014
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIRâ„¢ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Purpose CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized… (More)
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2013
2013
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
TRU-016 is a SMIP(TM) (monospecific protein therapeutic) molecule against the tetraspanin transmembrane family protein CD37 that… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Action of novel CD37 antibodies on chronic lymphocytic leukemia cells
Chronic lymphocytic leukemia (CLL) represents the most prevalent adult leukemia and is characterized by the accumulation of long… (More)
  • figure 1
  • figure 2
Is this relevant?
2011
2011
A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chronic lymphocytic leukemia.
e13053 Background: CD37 is a member of the tetraspanin superfamily of molecules, which are implicated in diverse processes… (More)
Is this relevant?
2009
2009
A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL.
3017 Background: CD37 is a tetraspan family member expressed predominantly on normal and transformed B-cells across a wide range… (More)
Is this relevant?
2009
2009
Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma.
8571 Background: TRU-016, a single chain anti-CD37 Fc fusion molecule has been shown to display pro-apoptotic and Fc-dependent… (More)
Is this relevant?
Review
2009
Review
2009
TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
TRU-016, under development by Trubion Pharmaceuticals Inc and Facet Biotech Corp, is an intravenously administered anti-CD37 IgG… (More)
Is this relevant?
2009
2009
Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM.
3035 Background: CD37 is a tetraspan transmembrane family protein selectively expressed on normal and transformed B-cells. A… (More)
Is this relevant?